DOACs are a newer class of anticoagulants that are more targeted and work faster than traditional options. They also don’t require frequent monitoring and have fewer dietary restrictions.

Direct oral anticoagulants (DOACs) are a group of medications doctors prescribe to prevent and treat blood clots. They inhibit specific factors in the blood coagulation process, reducing the risk of clot formation.

Doctors often prescribe them to treat and prevent conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.

Unlike traditional anticoagulants like warfarin, DOACs do not require frequent blood monitoring and have fewer dietary restrictions.

Read on to learn more about DOACs, including how they work, possible side effects, and considerations for their use.

DOACs vs. NOACs

Direct oral anticoagulants (DOACs) and novel oral anticoagulants (NOACs) are terms used interchangeably to describe newer blood-thinning medications that inhibit specific factors in the blood clotting process.

The main difference lies in the terminology, but both terms refer to the same group of medications.

“DOACs” is the preferred term to emphasize their direct action on clotting factors, while “NOACs” highlights their novel introduction compared to older therapies.

DOACs work by inhibiting specific proteins in the blood clotting process. Unlike traditional anticoagulants like warfarin, which act on multiple pathways, DOACs directly target either factor Xa or thrombin (factor IIa).

Factor Xa is an enzyme that converts prothrombin to thrombin, which is essential for clot formation. Thrombin then converts fibrinogen to fibrin, forming the clot. By inhibiting these proteins, DOACs effectively prevent blood clot formation.

This lowers the risk of stroke and other clot-related conditions such as deep vein thrombosis (DVT) and pulmonary embolism.

Doctors often prescribe DOACs for the following conditions:

DOACs help prevent stroke in people with AFib and manage or prevent the recurrence of DVT and pulmonary embolism.

Doctors may also prescribe DOACs after surgeries, such as hip or knee replacements, to prevent clots from forming.

It’s important to talk with a healthcare professional to get personalized medical advice on whether DOACs are suitable for you.

Common examples of direct oral anticoagulants include:

  • Dabigatran (Pradaxa): Pradaxa inhibits thrombin. It’s a capsule with a typical dosage of 150 milligrams (mg) twice daily. Doctors prescribe it for stroke prevention in people with AFib and to treat and prevent DVT and pulmonary embolism.
  • Rivaroxaban (Xarelto): Xarelto inhibits factor Xa. It’s available in tablet form with a dosage of 10 to 20 mg once daily. Doctors prescribe it to reduce the risk of stroke in AFib, treat and prevent DVT and pulmonary embolism, and prevent clots after surgery.
  • Apixaban (Eliquis): Eliquis targets factor Xa and comes in 2.5 mg and 5 mg tablets with varying dosages. It helps prevent stroke in people with AFib, treats and prevents DVT and pulmonary embolism, and prevents DVT after hip or knee replacement surgery.
  • Edoxaban (Savaysa): Savaysa also targets factor Xa. It’s available as a tablet, which doctors typically prescribe at a dosage of 60 mg once daily. It can help prevent stroke in people with AFib and treat DVT and pulmonary embolism after initial anticoagulant use.

DOACs have several benefits over traditional anticoagulants. These include:

  • No routine monitoring: Unlike warfarin (Coumadin, Jantoven), DOACs do not require regular blood testing to monitor their effectiveness.
  • Fewer dietary restrictions: People taking DOACs do not need to adhere to strict dietary restrictions.
  • Predictable pharmacokinetics: DOACs have predictable responses, making dosing simpler.
  • Rapid onset and offset: DOACs act quickly, providing rapid anticoagulation. Their effects also diminish faster when you stop taking the medication.
  • Reduced drug interactions: DOACs interact less with other medications than warfarin.

While DOACs are generally well-tolerated, they are not without risks.

As with all anticoagulants, there’s a risk of bleeding, including serious bleeding events such as gastrointestinal bleeding and intracranial hemorrhage.

Some people may also experience stomach upset or indigestion.

DOACs can interact with other medications, increasing the risk of bleeding or reducing their effectiveness. These medications include:

  • Antiplatelet drugs: Combining DOACs with medications like aspirin can increase bleeding risk.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs): These can also increase the likelihood of gastrointestinal bleeding.
  • Certain antibiotics and antifungals: Medications like clarithromycin or ketoconazole can alter the levels of DOACs in the blood.

To avoid potential interactions, it’s crucial to inform a healthcare professional of all medications and supplements you are taking.

Certain people should avoid direct oral anticoagulants:

  • People with severe kidney disease: Since the kidneys clear DOACs, severe impairment can lead to accumulation and increased bleeding risk.
  • People with mechanical heart valves: DOACs are not approved for people with mechanical heart valves as there’s not enough research to suggest they’re effective.
  • Active bleeding: Anyone experiencing significant bleeding should not take DOACs.

Is warfarin a direct oral anticoagulant?

No, warfarin is not a DOAC. It’s a vitamin K antagonist, an older type of anticoagulant that requires regular blood monitoring and dietary restrictions.

Is heparin a direct oral anticoagulant?

No, heparin is not a DOAC. It’s an injectable anticoagulant used in hospitals to prevent and treat blood clots.

DOACs effectively prevent and treat blood clots by inhibiting specific clotting factors. Doctors prescribe them for people with conditions like AFib, DVT, and pulmonary embolism.

DOACs offer several benefits, including no routine blood monitoring and fewer dietary restrictions. However, they’re not suitable for everyone and have some risks, such as bleeding and kidney function impairment.